Collegium Pharmaceutical (NASDAQ:COLL) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a report issued on Wednesday,Benzinga reports. Needham & Company LLC currently has a $46.00 price target on the specialty pharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the company. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock traded down $2.46 during trading on Wednesday, hitting $23.92. 156,604 shares of the company’s stock were exchanged, compared to its average volume of 440,418. The stock has a market capitalization of $768.44 million, a price-to-earnings ratio of 10.31 and a beta of 0.76. The business has a 50-day simple moving average of $29.36 and a 200-day simple moving average of $31.77. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. On average, research analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Colleen Tupper sold 977 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares of the company’s stock, valued at $4,928,070. This trade represents a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock worth $3,243,594 over the last quarter. 3.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently modified their holdings of COLL. FMR LLC raised its position in shares of Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after buying an additional 35,439 shares during the period. Verition Fund Management LLC increased its position in shares of Collegium Pharmaceutical by 35.1% during the 3rd quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company’s stock worth $543,000 after purchasing an additional 3,652 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 399.4% during the third quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock worth $2,686,000 after buying an additional 55,572 shares during the period. Wellington Management Group LLP boosted its stake in Collegium Pharmaceutical by 17.2% during the third quarter. Wellington Management Group LLP now owns 114,640 shares of the specialty pharmaceutical company’s stock worth $4,430,000 after buying an additional 16,784 shares during the period. Finally, Barclays PLC increased its position in shares of Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after acquiring an additional 45,291 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.